InvestWiser

Pharma Equity Group A/S Cl A

PEGNasdaq CopenhagenHealthcareMarket value 89 m DKK
0.07DKK −4.0%
last day · Price as of 18 November 2026

The answer first

Does Pharma Equity Group A/S Cl beat the market?

No, Pharma Equity Group A/S Cl has not beaten the market over the last year.

Pharma Equity Group A/S Cl−38.6%København (OMXCGI)+13.9%
  • The ranking · Quality, value and trend combined

    Better than 2% of Nordic stocks

    • Quality13
    • Value7
    • Trend24

    No. 187 of 195 in healthcare

Max for seven days

Follow Pharma Equity Group A/S Cl with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Pharma Equity Group A/S Cl

From today, at a price of 0.07 DKK. Write why you follow Pharma Equity Group A/S Cl, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Pharma Equity Group A/S Cl

Your first answer is free, no account needed.

Do you own Pharma Equity Group A/S Cl, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Pharma Equity Group A/S Cl and a few more. Free, no card.

Past year against the exchange and Super Stock
Pharma Equity Group A/S Cl−38.6%København (OMXCGI)+13.9%Super Stock+44.6%
13 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Pharma Equity Group A/S Cl has fallen 38.6% over the past year, including dividends.
  • Overall, Pharma Equity Group A/S Cl ranks better than 2% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 93.9%. The price is 99.9% below its peak now.

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

2

Quality, value and trend together. Better than 2% of Nordic stocks.

No. 187 of 195 in healthcare

Quality13
The company · Fundamentals: the accounts

Low Weaker accounts than most: low profitability, high debt or uneven results.

No. 182 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.44
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−72.0%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value7
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 151 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity3.3
  • P/SPrice divided by sales19.9
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend24
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 115 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−13.2%
  • 6 months−8.4%
  • 9 months−23.1%
  • 12 months−38.6%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−2.2%
3 years, per year
−45.6%
5 years, per year
−33.2%
10 years, per year
−25.1%
Largest fall, 3 years
−93.9%
From a peak to the bottom
From the peak now
−99.9%
How far the price is from the peak
Volatility, 1 year
81.2%
How much the price swings over a year
Beta, 1 year
−0.17
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Pharma Equity Group A/S Cl

4 funds we follow own Pharma Equity Group A/S Cl. The share is how much of the fund the stock makes up.

  • Denmark4

From the funds' latest known holdings.

About Pharma Equity Group A/S Cl

Pharma Equity Group A/S Cl A is a company in healthcare, listed on Nasdaq Copenhagen. The share trades in DKK. It has around 5 employees.

Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which the current therapy is lacking or in need of improvement. Its products under development, includes RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX-051 for the treatment of colorectal cancer and colon adenoma that are in Phase II clinical trials. The company was incorporated in 2002 and is headquartered in Horsholm, Denmark.

See the full analysis of Pharma Equity Group A/S Cl.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Copenhagen

Explore the stock market